{
  "context": {
    "rules": [
      "Rule1: Provided that a skilled technician is available for Drug Alpha, the equipment for Drug Alpha is functional.",
      "Rule2: Under the condition that quality assurance for Drug Alpha has passed, if equipment for Drug Alpha is functional, then production of Drug Alpha is not delayed.",
      "Rule3: Manufacturing of Drug Alpha begins only if Drug Alpha receives regulatory approval.",
      "Rule4: In the event that raw materials for Drug Alpha have arrived, the facility for Drug Alpha is ready.",
      "Rule5: Either raw materials for Drug Alpha have arrived, or an alternative supplier is used for Drug Alpha.",
      "Rule6: Provided that an alternative supplier is used for Drug Alpha, manufacturing of Drug Alpha begins.",
      "Rule7: Whenever venture capital is invested in Drug Alpha, Drug Alpha is profitable.",
      "Rule8: Provided that Drug Alpha is tested, Drug Alpha is safe.",
      "Rule9: Under the condition that a credit line for Drug Alpha is secured, a loan for Drug Alpha is denied.",
      "Rule10: Whenever a subsidy for Drug Alpha is approved, Drug Alpha is profitable.",
      "Rule11: Either Drug Alpha is patent protected, or if a government grant is received for Drug Alpha, then a subsidy for Drug Alpha is approved.",
      "Rule12: If legal action is taken against Drug Alpha, then a lawsuit is filed against Drug Alpha.",
      "Rule13: Provided that Drug Alpha receives fast track designation, if Drug Alpha does not receive regulatory approval, then Drug Alpha is approved.",
      "Rule14: Under the condition that Drug Alpha has orphan drug status, if Drug Alpha does not receive regulatory approval, then Drug Alpha is approved.",
      "Rule15: Given that insurance coverage is obtained for Drug Alpha, if Drug Alpha does not receive regulatory approval, then Drug Alpha is approved.",
      "Rule16: Provided that reimbursement for Drug Alpha is approved, if Drug Alpha does not receive regulatory approval, then Drug Alpha is approved.",
      "Rule17: If the supply chain for Drug Alpha is disrupted, then logistics for Drug Alpha are optimized.",
      "Rule18: Under the condition that the supply chain for Drug Alpha is disrupted, logistics for Drug Alpha are not optimized.",
      "Rule19: Whenever a contingency protocol for Drug Alpha is in place, a backup plan for Drug Alpha is activated.",
      "Rule20: Provided that equipment for Drug Alpha fails, if manufacturing of Drug Alpha does not begin, then a contingency protocol for Drug Alpha is in place.",
      "Rule21: Equipment for Drug Alpha fails or there is a personnel shortage for Drug Alpha.",
      "Rule22: If there is a personnel shortage for Drug Alpha, then if manufacturing of Drug Alpha does not begin, a contingency protocol for Drug Alpha is in place.",
      "Rule23: Provided that investment for Drug Alpha is secured, a government grant is received for Drug Alpha.",
      "Rule24: Given that Drug Alpha is profitable, if Drug Alpha is safe, then Drug Alpha is approved.",
      "Rule25: Under the condition that there is high market demand for Drug Alpha, if investment for Drug Alpha is secured, then Drug Alpha is profitable.",
      "Rule26: There is high market demand for Drug Alpha or a competitor of Drug Alpha has failed.",
      "Rule27: Provided that a competitor of Drug Alpha has failed, if investment for Drug Alpha is secured, then Drug Alpha is profitable.",
      "Rule28: If there is a regulatory hurdle for Drug Alpha, then production of Drug Alpha is delayed.",
      "Rule29: Either there is a regulatory hurdle for Drug Alpha, or Drug Alpha receives regulatory approval.",
      "Rule30: Whenever production of Drug Alpha is delayed, the supply chain for Drug Alpha is disrupted.",
      "Rule31: If it is not the case that if the facility for Drug Alpha is ready, then manufacturing of Drug Alpha begins, the project for Drug Alpha is canceled.",
      "Rule32: Provided that it is not the case that Drug Alpha receives fast track designation or Drug Alpha has orphan drug status, Drug Alpha faces regulatory rejection.",
      "Rule33: If it is not the case that Drug Alpha receives fast track designation or Drug Alpha has orphan drug status, then Drug Alpha does not face regulatory rejection.",
      "Rule34: Provided that it is not the case that insurance coverage is obtained for Drug Alpha or reimbursement for Drug Alpha is approved, the payment model for Drug Alpha is rejected.",
      "Rule35: Provided that it is not the case that if investment for Drug Alpha is secured, then venture capital is invested in Drug Alpha, a credit line for Drug Alpha is secured.",
      "Rule36: Under the condition that it is not the case that if investment for Drug Alpha is secured, then venture capital is invested in Drug Alpha, a loan for Drug Alpha is not denied.",
      "Rule37: Provided that it is not the case that if it is not the case that if Drug Alpha is safe, then Drug Alpha is approved, then a clinical trial for Drug Alpha has failed, then legal action is taken against Drug Alpha.",
      "Rule38: Under the condition that Drug Alpha does not receive regulatory approval, Drug Alpha is tested."
    ],
    "facts": [
      "Fact1: A skilled technician is available for Drug Alpha.",
      "Fact2: Quality assurance for Drug Alpha has passed.",
      "Fact3: Investment for Drug Alpha is secured.",
      "Fact4: It is not the case that Drug Alpha is approved.",
      "Fact5: The project for Drug Alpha is not canceled.",
      "Fact6: Drug Alpha is not patent protected.",
      "Fact7: A clinical trial for Drug Alpha has not failed.",
      "Fact8: A lawsuit is not filed against Drug Alpha.",
      "Fact9: The payment model for Drug Alpha is not rejected.",
      "Fact10: A backup plan for Drug Alpha is not activated."
    ]
  },
  "question": "Drug Alpha receives regulatory approval."
}